Funded Grants

Grants awarded in the current fiscal year and carried over from prior fiscal years.

PI Name Sort descending	PI Organization	Title	Grant Number	Initiative	Program Official
Carlson, Jay W	Ozark Health Ventures, Llc United States	Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO)	3UG1CA189822-11S1		Vanessa A. White, M.P.H.
Carson, Tiffany Lashaun	H. Lee Moffitt Cancer Ctr & Res Inst United States	Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults	5R01CA253219-06		Young Kim, Ph.D.
Castilla, Lucio H.	Univ Of Massachusetts Med Sch Worcester United States	Study of tyrosine kinase inhibitors as preventive therapy in RUNX1-FPD	1U01CA296350-01		Marjorie Perloff, M.D.
Castro, Cesar M	Massachusetts General Hospital United States	Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach	3U01CA279858-03S2		Christos Patriotis, Ph.D., M.Sc.
Caulin, Carlos	University Of Arizona United States	Genetic Alterations That Confer High Risk to Oral Premalignant Lesions	5R01CA274857-04	PA-20-185 (Parent R01 Clinical Trial Not Allowed)	John Clifford, Ph.D.
Caywood, Emi H	Nemours Children'S Hospital, Delaware United States	Nemours NCI Community Oncology Research Program (NCORP)	3UG1CA189958-11S1		Vanessa A. White, M.P.H.
Chak, Amitabh	Case Western Reserve University United States	Pathways of Injury and Repair in Barrett's Carcinogenesis	5P01CA269019-03		Asad Umar, D.V.M., Ph.D.
Chan, Andrew T	Massachusetts General Hospital United States	MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	3OT2CA297680-01S1		Asad Umar, D.V.M., Ph.D.
Chan, Andrew T	Massachusetts General Hospital United States	Precision Prevention Research Program	5R35CA253185-06		Asad Umar, D.V.M., Ph.D.
Chan, Daniel Wanyui	Johns Hopkins University United States	Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions	5U01CA274514-03	PAR-21-334 (U01 Clinical Trial Optional)	Matthew Young, Ph.D.